Computer-aided repositioning and functional in vitro assessment of novel PAD4 inhibitors

Abstract

Peptidyl arginine deiminase 4 (PAD4) is a protein that catalyzes both normal and abnormal citrullination of interacting protein partners, affecting gene regulation and being associated with diseases such as Alzheimer, cancer, and rheumatoid arthritis (RA). As a result, PAD4 has emerged as a potential therapeutic target; however, no inhibitors have been approved to date. In this study, the REFRAME and ZINC15 drug databases were virtually screened. The approach used molecular docking and dynamics simulation techniques to identify compounds with high predicted binding affinity to PAD4 (PDB ID: 4DKT). Selected hits from this virtual screening underwent in vitro assays using fixed concentrations derived from docking score to evaluate their ability to inhibit PAD4 activity, and their effect on neutrophil extracellular trap (NETs) release was assessed using an ex vivo human neutrophil model. Computational analyses identified amodiaquine, folic acid, and pyroxamide as stable PAD4 binders. In vitro inhibition assays revealed that amodiaquine (5.0 µM to 1.0 nM) and pyroxamide (0.1 µM) were more potent inhibitors than the reference PAD4 inhibitor BBCla (8.8 µM), while folic acid showed a non-significant trend toward inhibition. Cytotoxicity assays confirmed that all compounds were non-toxic at the tested concentrations, except for amodiaquine at 50 µM. NETosis assays demonstrated that the three selected compounds altered chromatin decondensation and cellular morphology similarly to BBCla, although not uniformly across all cells. Overall, amodiaquine, folic acid, and pyroxamide were identified as PAD4 inhibitors through combined virtual and experimental approaches, supporting their potential as therapeutic candidates for PAD4-related diseases and warranting further investigation.

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Research Article
Submitted
06 May 2025
Accepted
29 Jun 2025
First published
30 Jun 2025

RSC Med. Chem., 2025, Accepted Manuscript

Computer-aided repositioning and functional in vitro assessment of novel PAD4 inhibitors

S. Ruíz-Hernández, F. D. L. Ochoa-González, J. E. Castañeda-Delgado, O. G. Galicia-Cruz, R. Castillo-Velázquez, M. Comas-García, G. Rivera and E. E. Lara-Ramírez, RSC Med. Chem., 2025, Accepted Manuscript , DOI: 10.1039/D5MD00395D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements